Confluent, Scottsdale, AZ, announced a partnership with ATI to invest over $50 million in expanding ATI’s Nitinol melt and materials conversion infrastructure. This investment will more than triple ATI’s melt capacity for medical Nitinol, with Confluent becoming ATI’s fulfillment partner. Confluent will provide value-added services and order fulfillment for ATI’s medical Nitinol mill products.
Dean Schauer, CEO and president of Confluent, highlighted the demand growth in the Neurovascular, Electrophysiology, Structural Heart, Peripheral Vascular, and Orthopedic device markets, which is driving an 18% growth rate (CAGR) in Nitinol demand. Schauer emphasized that the industry has struggled to support this growth due to the substantial equipment and infrastructural costs needed to increase supply chain capacity. Confluent’s investment aims to provide the necessary mid-term and long-term melt and conversion capacity to meet this demand, ensuring a reliable supply chain for OEM customers.
Rob Foster, president of ATI’s Specialty Alloys & Components business, expressed appreciation for Confluent’s investment and trust in ATI’s expertise. Foster noted that this partnership would ensure a stable supply of Nitinol, crucial for the industry’s growth. The expansion at ATI’s Millersburg, Oregon facility is expected to be operational by 2027.
With these expanded capabilities, Confluent will continue to offer a reliable supply chain, delivering a comprehensive range of medical Nitinol services, including mill products, hollows, tubes, wires, and components.
